| 3 | 1/1 | 返回列表 |
| 查看: 1602 | 回復(fù): 2 | |||
解說(shuō)國(guó)自然捐助貴賓 (小有名氣)
|
[交流]
新規(guī)則下,醫(yī)生還能不能安心發(fā)SCI論文了? 已有2人參與
|
|
近幾天來(lái),大家都在瘋傳ICMJE的新規(guī)則:Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors。 在新規(guī)則下,醫(yī)生還能不能好好發(fā)SCI論文了?因此,今天我們的主題是“目前國(guó)內(nèi)醫(yī)學(xué)SCI投稿最大的障礙與ICMJE的新規(guī)則:動(dòng)物倫理、臨床試驗(yàn)倫理及臨床試驗(yàn)注冊(cè)”。我們?cè)谝?guī)劃SCI前,一定要將非學(xué)術(shù)的問題解決好! 我們主要從三個(gè)方面來(lái)討論。最后討論ICMJE的最新規(guī)則。 1、動(dòng)物倫理和臨床試驗(yàn)的倫理:課題設(shè)計(jì)完成,在開始實(shí)驗(yàn)/試驗(yàn)之前,一定要拿到動(dòng)物倫理和臨床試驗(yàn)的倫理。倫理問題,尤其是臨床試驗(yàn)的倫理,是比較重要的,一定要有。當(dāng)然,目前關(guān)于動(dòng)物倫理,也已有SCI期刊要求提供。 請(qǐng)看我們投稿后,編輯部在2017年的回復(fù)郵件中提出的意見,是不是很“驚喜”: Title: *** Dear Professor ***, Please provide the name of the committee from which you received ethical approval for the use of rats in your study, and provide evidence of this approval. 。。。 Yours sincerely, *** 2、臨床試驗(yàn)注冊(cè):課題設(shè)計(jì)完成后,臨床試驗(yàn)的課題,對(duì)于“臨床試驗(yàn)注冊(cè)”,大家也一定要注意,沒有注冊(cè),估計(jì)后續(xù)會(huì)沒有機(jī)會(huì)投稿。這個(gè)問題,似乎大家重視程度不夠。 大家請(qǐng)看我們這兩年遇到的一種情況,同時(shí)也有幾個(gè)朋友反映:文章投稿后就拒稿,沒有任何反饋意見。經(jīng)過我們分析后,估計(jì)也是因?yàn)榕R床試驗(yàn),沒有倫理或者臨床試驗(yàn)注冊(cè)。 大家先請(qǐng)看要求提供臨床試驗(yàn)注冊(cè)的郵件(郵件是2015年編輯部回復(fù)的): Dear Dr. **: Before proceeding with the review orioles can you confirm the clinical trial registry number?(編輯部要求我們提供臨床試驗(yàn)注冊(cè)的注冊(cè)號(hào)). I look forward to hearing from you. Sincerely, Dr. ** Journal of *** 大家再來(lái)看看編輯部因?yàn)樽髡邲]有按照ICMJE規(guī)則要求來(lái)注冊(cè),沒有提前注冊(cè)而是后補(bǔ)注冊(cè)的后果(這個(gè)來(lái)自2016年編輯部的郵件): Dear Dr. **, Many thanks for clarifying the status of your clinical trial registration. Unfortunately, I cannot consider your manuscript further. As a journal, we adhere to the ICMJE guidelines, which require prospective trial registration(ICMJE的要求,前瞻性研究的臨床試驗(yàn),必須在納入第一例病人前完成臨床試驗(yàn)注冊(cè)). In spite of the present decision, we look forward to submissions from you in the future. Thank you for submitting your manuscript to the Journal of ***. Yours sincerely Dr. *** 然而,到這里,大家是不是認(rèn)為:在還沒有開始臨床試驗(yàn)前,僅僅注冊(cè)就可以了呢?看看下面最新的要求吧,目前的要求是越來(lái)越高! 3、ICMJE的新規(guī):臨床試驗(yàn)注冊(cè)的數(shù)據(jù),必須全部公開!!這是最新的要求,就在6月初公布的。大家請(qǐng)看:Data Sharing Statements for Clinical Trials — A Requirement of the International Committee of Medical Journal Editors。 什么?什么?要全部公開?這是怎么回事??新規(guī)則下,醫(yī)生還能不能好好發(fā)SCI論文了? 首先,我們看看ICMJE的要求是哪些?下圖是ICMJE要求中提供的最新內(nèi)容: Therefore, ICMJE will require the following as conditions of consideration for publication of a clinical trial report in our member journals: 1. As of July 1, 2018, manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement as described below. 2. Clinical trials that begin enrolling participants on or after January 1, 2019, must include a data sharing plan in the trial’s registration. The ICMJE’s policy regarding trial registration is explained at https://www.icmje.org/recommenda ... -registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript and updated in the registry record. 簡(jiǎn)單翻譯一下,就是: 第一,2018年7月及以后提交到ICMJE期刊的臨床試驗(yàn)報(bào)告,必須包含數(shù)據(jù)共享聲明。 第二,2019年1月1日后開始入組受試者的臨床試驗(yàn),必須在臨床試驗(yàn)注冊(cè)平臺(tái)上提交數(shù)據(jù)共享計(jì)劃。 ICMJE為何這么牛氣?我們來(lái)看看ICMJE的情況,ICMJE是International Committee of Medical Journal Editors(國(guó)際醫(yī)學(xué)期刊編輯委員會(huì))的簡(jiǎn)稱。 ICMJE的成員包括哪些期刊呢?醫(yī)學(xué)領(lǐng)域的話,我們搜索了一下ICMJE的網(wǎng)站(https://www.icmje.org/)。 像什么NEJM、JAMA、Lancet、BMJ、Plos等都是ICMJE的成員。這個(gè)新的聲明,估計(jì)后面會(huì)有全文的翻譯版,目前在各大醫(yī)學(xué)期刊上全文基本上都是免費(fèi)下載的,大家可以自行前往查閱: https://www.nejm.org/doi/full/10.1056/NEJMe1705439; https://jamanetwork.com/journals/jama/fullarticle/2630773; https://www.thelancet.com/journa ... 17)31282-5/fulltext; 綜上所述,后續(xù)大家在設(shè)計(jì)醫(yī)學(xué)方面課題時(shí),尤其是在實(shí)施前,各個(gè)規(guī)則都要考慮。不然,會(huì)給后面的發(fā)表帶來(lái)不可控制的損失。新規(guī)則下,醫(yī)生要想好好發(fā)SCI論文,就得遵守ICMJE的規(guī)則。 在投稿過程,編輯部返回的意見中,有的期刊在拒稿信中會(huì)寫明需要遵守ICMJE和臨床試驗(yàn)注冊(cè);而有的期刊只用一句話:不符合我們期刊刊文要求!草草打發(fā)掉,根本就不告訴我們到底是哪兒不符合,甚至發(fā)郵件咨詢,編輯部還會(huì)說(shuō)詳情在for authors中。。。您老倒是告訴我們哪兒不行?? Title: ****** Corresponding Author: Prof. *** Authors:****** Dear Prof. ***, Thank you for your submission to ***. Unfortunately, I feel that your paper is not suitable for publication in the journal and unlikely to be favorably reviewed by the referees, or lies outside the scope of the journal. Thank you for your interest in ***. Sincerely, ***, M.D. Regional Editor |
|
本帖內(nèi)容被屏蔽 |
| 。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。 |
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 085600,專業(yè)課化工原理,320分求調(diào)劑 +4 | 大饞小子 2026-03-29 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 085600 286分 材料求調(diào)劑 +10 | 麻辣魷魚 2026-03-27 | 11/550 |
|
|
[考研] 一志愿哈爾濱工業(yè)大學(xué)材料與化工方向336分 +10 | 辰沐5211314 2026-03-26 | 10/500 |
|
|
[考研] 一志愿:西北大學(xué),英一數(shù)一408-284分求調(diào)劑 +4 | 12.27 2026-03-27 | 4/200 |
|
|
[碩博家園] 招收生物學(xué)/細(xì)胞生物學(xué)調(diào)劑 +4 | IceGuo 2026-03-26 | 5/250 |
|
|
[考研] 295求調(diào)劑 +4 | wei-5 2026-03-26 | 4/200 |
|
|
[考研] 083000學(xué)碩274求調(diào)劑 +8 | Li李魚 2026-03-26 | 8/400 |
|
|
[考研] 復(fù)試調(diào)劑 +3 | raojunqi0129 2026-03-28 | 3/150 |
|
|
[材料工程] 一志愿C9材料與化工專業(yè)總分300求調(diào)劑 +8 | 曼111 2026-03-24 | 9/450 |
|
|
[考研] 266求調(diào)劑 +11 | 陽(yáng)陽(yáng)哇塞 2026-03-27 | 12/600 |
|
|
[考研] 安徽大學(xué)專碩生物與醫(yī)藥專業(yè)(086000)324分,英語(yǔ)已過四六級(jí),六級(jí)521,求調(diào)劑 +4 | 美味可樂雞翅 2026-03-26 | 4/200 |
|
|
[考研] 復(fù)試調(diào)劑,一志愿南農(nóng)083200食品科學(xué)與工程 +5 | XQTJZ 2026-03-26 | 5/250 |
|
|
[考研] 考研調(diào)劑 +10 | 呼呼?~+123456 2026-03-24 | 10/500 |
|
|
[考研] 求調(diào)劑 一志愿 本科 北科大 化學(xué) 343 +6 | 13831862839 2026-03-24 | 7/350 |
|
|
[考研] 327求調(diào)劑 +7 | prayer13 2026-03-23 | 7/350 |
|
|
[考研] 一志愿哈工大,085400,320,求調(diào)劑 +4 | gdlf9999 2026-03-24 | 4/200 |
|
|
[考研] 考研一志愿蘇州大學(xué)初始315(英一)求調(diào)劑 +3 | sbdksD 2026-03-24 | 4/200 |
|
|
[考研] 0854人工智能方向招收調(diào)劑 +4 | 章小魚567 2026-03-24 | 4/200 |
|
|
[考研] 材料調(diào)劑 +3 | iwinso 2026-03-23 | 3/150 |
|
|
[考研] 調(diào)劑 +4 | 13853210211 2026-03-24 | 4/200 |
|